These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16538785)

  • 1. High-dose chemotherapy for ERBB2-negative breast cancer.
    Owen OG
    Lancet Oncol; 2006 Mar; 7(3):201. PubMed ID: 16538785
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer.
    Buzdar AU; Smith TL; Marcus CE; Hortobagyi GN; Blumenschein GR
    Recent Results Cancer Res; 1984; 96():141-7. PubMed ID: 6396767
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
    Hirte HW; Hotte SJ
    J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
    [No Abstract]   [Full Text] [Related]  

  • 6. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.
    Goldhirsch A; Glick JH; Gelber RD; Senn HJ
    J Natl Cancer Inst; 1998 Nov; 90(21):1601-8. PubMed ID: 9811309
    [No Abstract]   [Full Text] [Related]  

  • 7. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
    J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.
    Fehm T; Maimonis P; Weitz S; Teramoto Y; Katalinic A; Jäger W
    Breast Cancer Res Treat; 1997 Mar; 43(1):87-95. PubMed ID: 9065602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients.
    Revillion F; Hebbar M; Bonneterre J; Peyrat JP
    Eur J Cancer; 1996 Feb; 32A(2):231-4. PubMed ID: 8664033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results.
    Senn HJ; Jungi WF; Amgwerd R; Hochuli E; Ammann J; Engelhart G; Heinz C; Wick A; Enderlin F; Creux G
    Recent Results Cancer Res; 1984; 96():90-101. PubMed ID: 6528092
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving concepts in the systemic adjuvant treatment of breast cancer.
    Bonadonna G
    Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose chemotherapy for breast cancer.
    Nieto Y; Shpall EJ
    Cancer Treat Res; 2000; 103():77-114. PubMed ID: 10948443
    [No Abstract]   [Full Text] [Related]  

  • 15. The sound and the fury: an update on the role of high-dose chemotherapy and autologous stem cell salvage for both metastatic and high-risk breast cancer.
    Bar MH
    Conn Med; 2000 Jan; 64(1):3-6. PubMed ID: 10697358
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adjuvant therapy in breast cancer].
    Semiglazov VF
    Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
    Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D
    Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical relevance of the overexpression of HER-2 in breast cancer].
    Khosravi Shahi P; Pérez Manga G
    An Med Interna; 2006 Mar; 23(3):103-4. PubMed ID: 16737428
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current review and status of IHC and FISH in breast carcinoma. Role of further diagnostic methods].
    Lebeau A
    Onkologie; 2002 Dec; 25 Suppl 5():5-7. PubMed ID: 23573610
    [No Abstract]   [Full Text] [Related]  

  • 20. CMF adjuvant programs at the Milan Cancer Institute.
    Bonadonna G; Rossi A; Tancini G; Valagussa P; Veronesi U
    Recent Results Cancer Res; 1984; 96():66-73. PubMed ID: 6549356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.